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Abstract
Interferon inducible protein kinase PKR is an essential component of innate immunity. It is activated by long stretches of
dsRNA and provides the first line of host defense against pathogens by inhibiting translation initiation in the infected cell.
Many cellular and viral transcripts contain nucleoside modifications and/or tertiary structure that could affect PKR activation.
We have previously demonstrated that a 59-end triphosphate–a signature of certain viral and bacterial transcripts–confers
the ability of relatively unstructured model RNA transcripts to activate PKR to inhibit translation, and that this activation is
abrogated by certain modifications present in cellular RNAs. In order to understand the biological implications of native RNA
tertiary structure and nucleoside modifications on PKR activation, we study here the heavily modified cellular tRNAs and the
unmodified or the lightly modified mitochondrial tRNAs (mt-tRNA). We find that both a T7 transcript of yeast tRNAPhe and
natively extracted total bovine liver mt-tRNA activate PKR in vitro, whereas native E. coli, bovine liver, yeast, and wheat
tRNAPhe do not, nor do a variety of base- or sugar-modified T7 transcripts. These results are further supported by activation
of PKR by a natively folded T7 transcript of tRNAPhe in vivo supporting the importance of tRNA modification in suppressing
PKR activation in cells. We also examine PKR activation by a T7 transcript of the A14G pathogenic mutant of mt-tRNALeu,
which is known to dimerize, and find that the misfolded dimeric form activates PKR in vitro while the monomeric form does
not. Overall, the in vitro and in vivo findings herein indicate that tRNAs have an intrinsic ability to activate PKR and that
nucleoside modifications and native RNA tertiary folding may function, at least in part, to suppress such activation, thus
serving to distinguish self and non-self tRNA in innate immunity.
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Introduction
Interferon-inducible PKR is a vital component of innate
immunity, which provides the first line of defense against
pathogens [1,2]. PKR consists of two functional domains: an N-
terminal double stranded RNA (dsRNA) binding domain (dsRBD)
comprised of two dsRNA binding motifs (dsRBMs) and a C-
terminal kinase domain. These domains are separated by a flexible
20 amino acid linker [3,4]. The dsRBM recognizes dsRNA with
no sequence specificity via minor groove interactions [5,6], while
the kinase domain helps mediate dimerization of PKR as well as
possessing the kinase catalytic activity [7–9].
Activation of PKR is well known to be promoted by long
stretches of dsRNA (.33 base pairs), which may arise as
intermediates during viral replication. RNA species of this length
are long enough to accommodate a PKR dimer [10–12]. Two
models of RNA-mediated activation of PKR have been offered: 1)
a model in which PKR has intrinsically disordered regions that
become ordered upon RNA binding, and 2) an autoinhibition
model in which the latent protein is locked into a closed
conformation that is relieved upon binding to dsRNA of sufficient
length [3,13]. Activated PKR then phosphorylates translation
initiation factor eIF2a, inhibiting translation initiation [14]. This
overall process provides essential antiviral and antiproliferative
functions for the infected host cell [15].
In addition to the above functions, PKR has been shown to
modulate cell-signaling pathways, which alter numerous cellular
responses [16]. For instance, PKR regulation has been linked to
several diseases, including Huntington’s, Parkinson’s and Alzhei-
mer’s disease [17–21]. Furthermore, recent studies indicate that
PKR regulates insulin action and metabolism in response to
nutrient signals and endoplasmic reticulum stress [22].
A number of different RNAs beyond long, perfect dsRNA
activate PKR [1,23]. For instance, certain highly structured single-
stranded viral and cellular RNAs with bulges, imperfect loops,
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pseudoknots, and single stranded tails can activate PKR [24–26].
In addition, largely single-stranded RNA can activate PKR in a 59-
triphosphate dependent manner, which may help distinguish self
and non-self RNAs [27–29], and this activation can be abrogated
by incorporating nucleoside modifications into the transcripts
[30,31]. Several examples of non-canonical RNA activators of
PKR include: HIV TAR and HDV RNA dimers [10,11], domain
II and domain III–IV of the internal ribosome entry site (IRES) of
HCV [32,33], the 39-untranslated regions (UTRs) of several highly
structured cytoskeletal mRNAs [34,35], the 59-UTR of IFN-c
mRNA [24,25], and mutant transcripts of the Huntington’s and
myotonic dystrophy protein kinase (DMPK) genes [18,36,37].
These non-canonical RNA activators provide an activating length
of 33 bp by either dimerization of the RNA [10,11], which
roughly doubles the length of a given RNA species, or by non-
Watson-Crick interactions in the loops of the RNA [1,25]. In
addition, siRNA containing just 19–21 bp can activate PKR,
possibly by forming extended RNA species [1,38,39].
Another important biological RNA that has so far not been
studied with respect to PKR regulation is transfer RNA (tRNA).
The folding of tRNAs conforms to a cloverleaf secondary structure
and requires magnesium [40] and post-transcriptional modifica-
tions [41–43] in order to achieve high tertiary structure stability.
Studies have shown that an unmodified tRNA transcript of yeast
tRNAPhe can be aminoacylated and has a similar lead cleavage
pattern, indicating that the tertiary structure of this unmodified T7
tRNA transcript is similar to that of native tRNA [41,42].
Likewise, the crystal structure of an unmodified E. coli tRNAPhe
has an overall fold that is nearly identical to that of the native
tRNA [44].
Several studies suggest that tRNAs have a tendency to dimerize
and that such dimers are separable by analytical techniques.
Examples of dimerizing tRNAs include tRNATyr [45] and
tRNAGlu [46] from E.coli; tRNAAla from yeast [47]; and a mutant
form of mitochondrial tRNALeu [48,49]. Given that modifications
in tRNA strengthen tertiary structure [41–43], one function of
modifications might be to favor native RNA tertiary structure and
thereby minimize tRNA dimerization. This observation could be
related to innate immunity given previous data indicating that
RNA dimerization drives PKR activation [10,11]. In addition,
previous studies suggest that unmodified tRNAs are capable of
inducing an innate immune response via tumor necrosis factor-
alpha (TNF-a) in dendritic cells through Toll-like receptors
(TLRs), whereas this induction is abrogated by modified tRNA
[50]. The effect of nucleoside modifications and the function of
dimers in tRNA have not been probed for regulation of PKR.
We recently reported that naturally occurring nucleoside
modifications modulate PKR activation in an RNA structure-
specific manner [30]. Introduction of most RNA modifications
into a largely single-stranded RNA 47mer, ‘‘ssRNA-47’’ that
activates PKR in a 59-triphosphate-dependent manner [27] were
found to abrogate activation, whereas just a few of these
modifications abrogated PKR activation by perfectly dsRNA. In
the present study, we evaluate PKR activation by incorporating
nucleoside modifications into biologically relevant tRNA tran-
scripts, as well as endogenous tRNAs from various organisms. In
the cytoplasm of the cell, tRNAs are the most heavily modified
RNAs, with approximately 20% of its nucleosides being modified
[51]. Since PKR is mostly present in the cytoplasm [52] and based
on our previous studies on modified short RNAs and mRNAs
[30,31], we reasoned that modifications in tRNAs may have a
significant role in suppressing activation of PKR.
Overall, we find that unmodified tRNAs activate PKR and that
this activation is abrogated by incorporating numerous modifica-
tions into tRNAs. Moreover, we demonstrate that in some cases,
tRNA dimers activate PKR, whereas monomers do not. General
implications of RNA lacking nucleoside modifications and native
tertiary structure for the innate immune response to pathogens are
discussed.
Results and Discussion
Most Nucleoside Modifications Abrogate Activation of
PKR by tRNA
In order to assess the effect of nucleoside modifications on
PKR activation by tRNA, we chose to examine the commer-
cially available phenylalanine-specific tRNA from yeast
(tRNAPhe) as an RNA substrate (Fig. 1A). At first we compared
activation (i.e. phosphorylation) of PKR by the T7 transcript of
tRNAPhe and the natively isolated tRNAPhe (Fig. 1B, row 1,
compare the two lane sets). (In an innate immune response,
PKR autophosphorylates, which allows it to phosphorylate
eIF2a which inhibits translation initiation.) The T7 transcript
contains a 59-triphosphate and unmodified bases, whereas the
native tRNA has a 59-monophosphate and modified bases. The
T7 transcript activated PKR to almost the same levels as the
perfectly double stranded, dsRNA-79, whereas native tRNAPhe
did not activate PKR above background at any of the RNA
concentrations tested (Fig. 1B). The abrogation of PKR
activation by native tRNAPhe may be due to the internal
modifications or to lack of a 59-triphosphate, given that some
RNAs require a 59-triphosphate to activate PKR [27]. To test
the role of the 59-triphosphate, we tested PKR activation by calf
intestinal phosphatase (CIP)-treated T7-tRNAPhe. Activation of
PKR was completely retained by CIP-treated T7-tRNAPhe
(Fig. 1B, row 2, compare ‘59-ppp’ and ‘59-OH’ lanes), indicating
that the 59-triphosphate is not a factor for PKR activation by
T7-tRNAPhe. The unimportance of a 59-triphosphate for tRNA-
PKR function is similar to that found for dsRNA and PKR
[27]. Overall, these findings suggest that nucleoside modifica-
tions may play a key role in abrogating PKR activation by
native tRNAPhe.
In order to better understand the role of nucleoside
modifications in native tRNA-PKR interactions, we tested
PKR activation by a series of modified T7-tRNAPhe transcripts.
We fully substituted uridines in tRNAPhe with either 2-
thiouridine (s2U) or pseudouridine (y); cytidine with either 5-
methylcytidine (m5C), 29-O-methylcytidine (Cm), or 29-fluorocy-
tidine (29-FC); and adenosine with N1-methyladenosine (m1A)
(Fig. 1B). These modified nucleosides are commercially available
as triphosphates, which are amenable for use in in vitro
transcription. Transfer RNAs containing the majority of these
modifications (s2U, y, m5C, Cm, and m1A) revealed significant
reduction in PKR activation, the exception being 29-FC, which
showed an enhancement in PKR activation. These results indicate
that modifications generally abrogate activation of PKR by
tRNA, just as observed previously in model RNAs [30].
Moreover, retention of PKR activation by tRNAs containing
29-FC, which can accept a hydrogen bond, supports the
importance of minor groove hydrogen bonding between the
dsRBD and tRNA, as previously reported in unmodified
dsRNAs [5,6]. In considering these data, it is important to
keep in mind that full substitution of a natural base with a
modified one will affect the folding of the tRNA; as such,
changes in PKR activation will be due to a combination of
direct effects of the modification and indirect effects of the RNA
folding. Overall, these findings suggest that tRNA has the
tRNA and PKR Activation
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potential to activate PKR and thus lead to an innate immune
response.
Mitochondrial tRNAs Activate PKR, Other Native tRNAs
do not
The level of modification in tRNA varies depending on the
origin of the tRNA. For example, cytoplasmic tRNAs are heavily
modified (,14 sites/tRNA), whereas mitochondrial tRNAs
generally contain relatively few modifications (,3 sites/tRNA)
and have less variety in the modifications observed [53]. In
particular, tRNAs from E. coli, bovine liver, yeast, and wheat
contain many modifications as compared to mitochondrial bovine
liver tRNAs [54]. To further test our observation that nucleoside
modifications in tRNA influence PKR activation, we tested PKR
activation by total tRNAs from different organisms, including E.
coli, bovine liver, yeast, wheat and bovine liver mitochondria. All
of these tRNAs are available commercially except for mitochon-
drial tRNA, which was isolated using published procedures [55].
As shown in Figure 2A, total mitochondrial bovine liver tRNA
significantly activated PKR, while total tRNAs from other
organisms did not. For example, at a 1.25 mM concentration,
tRNAs from E. coli, bovine liver, yeast and wheat showed lower
activation of PKR by ,22-, 7-, .25- and 7-fold, respectively, as
compared to mitochondrial tRNA. These observations strongly
suggest that nucleoside modifications in these tRNAs play a major
role in the abrogation of PKR activation, either directly or
through their effects on tRNA structure.
We next compared PKR activation by a natively isolated
methionine-specific mitochondrial tRNA (mt-tRNAMet) to activa-
tion by an in vitro transcribed version (T7-mt-tRNAMet). Remark-
ably, both of these tRNAs potently activated PKR, having
activation profiles similar to each other and to the total mt bovine
liver preparation, although there was somewhat less activation by
the native mt-tRNA, perhaps reflecting a slight suppression of
activation by its few modifications (Fig. 2B). Because in vitro
transcribed T7-mt-tRNAMet has no modifications and native mt-
tRNAMet has very few, we believe that the ability of these tRNAs
to activate PKR resides in the little or no modification present in
them. This interpretation supports the notion that modifications in
cytoplasmic tRNA play a significant role in minimizing PKR
activation either directly or through effects on tRNA structure.
Lastly, these results further support our earlier conclusion that
PKR activation by tRNA is not 59-triphosphate-dependent in that
neither of these tRNAs has a 59-triphosphate yet they are both
potent activators: the unmodified T7-mt-tRNAMet has a hammer-
head ribozyme-generated 59-hydroxyl while the natively isolated
mt-tRNAMet has a 59-monophosphate.
Activation of PKR by a mt-tRNA Dimer
Previous reports indicated that tRNAs are intrinsically capable
of forming dimers [45–49]. This tendency may be due to their
simple secondary structure, which is always at least partially self-
complementary. We, therefore, tested our various tRNAs for
dimer formation. When we performed native gel analysis on
unmodified radiolabeled T7 yeast tRNAPhe we detected a few
percent dimer, which, while more than detected in naturally
modified yeast tRNAphe, was not enough to purify (Fig. S1 in File
S1). We then turned to a human mitochondrial tRNA.
Human mitochondrial tRNALeu has been reported to form a
stable dimer when the pathogenic A14G mutation occurs [48].
This dimer can be separated from the monomer using native
PAGE purification, and its secondary structure has been
previously probed and shown to involve six GC base pairs in the
D stem-loop (Fig. 3A) [49]. We first confirmed dimerization of mt-
tRNALeu (A14G) using native gel electrophoresis under slightly
modified conditions. As shown in Figure 3B, the dimer band is
only observed in the A14G lanes, with more than 50% of the
tRNA forming a dimer under all temperature renaturation
conditions. (The identity of this species as a dimer has been
confirmed previously by native gel markers [48].).
Next, we investigated activation of PKR by dimers and
monomers of mitochondrial tRNALeu. The dimer was annealed
and purified as described in the Materials and Methods. Purified
dimer was stable when stored at 220uC, as checked by 32P-
radiolabeling analysis (e.g. Fig. 4B, 4C). In addition, we isolated
the mt-tRNALeu (WT) monomer on a native gel in order to
eliminate any dimeric form.
Upon testing the activation of PKR by dimers and monomers
of mt-tRNALeu, the tRNA dimer activated PKR, whereas the
tRNA monomer did not (Fig. 4A). In fact, no appreciable
activation of PKR by tRNA monomer was observed even at
concentrations up to 5 mM. In addition, the dimer tRNA
(A14G) activated PKR to the same levels as perfect dsRNA-79
(Fig. 4A). This result clearly shows that the dimeric form of this
tRNA is an activator of PKR.
It has been shown that 16 bp of dsRNA is required for binding
to PKR and that 30 bp is required for activation [5,12,56,57].
Moreover, the dsRBD can tolerate non-Watson-Crick base pairs,
and noncontiguous helical stems can help PKR dimerize for
activation [1,58]. In the dimeric form of mt-tRNALeu, 6 extra base
pairs form (Fig. 3A) [49]. Thus, while only ,20 base pairs are
present in monomeric mt-tRNALeu, ,40 base pairs are present in
dimeric mt-tRNALeu, which may be sufficient for PKR binding
and activation.
Next, we analyzed binding of PKR to both the monomeric
and dimeric forms of mt-tRNALeu. Native mobility-shift
experiments were carried out as previously described, using
P20, the dsRBD of PKR [5]. Appreciable binding was observed
for dimer (Kd,1 mM) compared to monomer (Kd,5 mM) in the
presence of 0.1 mg/mL herring sperm DNA (Fig. 4B). More-
over, the binding ability of the monomer was completely
abolished (Kd .20 mM) when 0.1 mg/mL native yeast tRNA
Phe
was used as a competitor, while the binding ability of the dimer
was reduced just 2.4-fold (Kd,3 mM) (Fig. 4C). These results
strongly suggest that the dimer is capable of binding PKR with
high affinity as compared to the monomer. Overall, the
approximate doubling of the number of base pairs present in
the tRNA dimer helps promote tight binding and activation of
PKR, as observed for other RNAs [10,11].
Figure 1. Effect of tRNA modifications on PKR activation. (A) Secondary structure of tRNAPhe in the cloverleaf representation. Positions of
modifications are depicted in bold font, where m2G = N2-methylguanosine, D = dihydrouridine, m22G = N2,N2-dimethylguanosine, Cm = 29-O-
methylcytidine, Gm = 29-O-methylguanosine, y= pseudouridine, m7G = 7-methylguanosine, m5C = 5-methylcytidine, and m1A = 1-methyladenosine,
Y = wybutosine. (B) Activation assays for modified tRNAs (10% SDS-PAGE). RNA concentrations are 0.31, 0.63, 1.25, 2.5, 5, and 10 mM. A no RNA control
and a positive control of 0.1 mM dsRNA-79 are included. Positions of modifications are depicted, where 59-ppp = triphosphate at 59-terminus (present
on all transcripts, unless otherwise noted), 59-OH = hydroxyl at 59-terminus, s2U = 2-thiouridine, m5C = 5-methylcytidine, 29-FC = 29-fluorocytidine,
and, m1A, and Cm are as defined in panel A. Phosphorylation activities are provided below each gel lane. Phosphorylation activities were normalized
to dsRNA-79 and rounded to the nearest integer.
doi:10.1371/journal.pone.0057905.g001
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Activation of PKR by tRNA in vivo
We wanted to test whether PKR is activated by unmodified
tRNA in cells. The Huh-7 cell line was chosen because it can
produce interferon (IFN)-a/b and has the capacity to signal from
the IFN-a/b receptor [27]. These cells can thus lead to PKR
phosphorylation without the addition of IFN. Transfection with
the positive control of dsRNA-79 induced activation of PKR
(Fig. 5, lane 2), while the mock transfection with RNA omitted did
not (Fig. 5, lane 1). Transfections of Huh-7 cells with a T7
transcript of yeast tRNAphe or natively isolated yeast tRNAphe
were also conducted. The T7 transcript induced activation of
PKR to the same level as the same amount of dsRNA-79 (Fig. 5,
compare lanes 4 and 2, respectively), while native tRNAphe did not
activate PKR above the background found in the mock lane
(Fig. 5, compare lanes 3 and 1, respectively). These results parallel
those found in vitro (Fig. 1B) and indicate that tRNAs have an
intrinsic ability to activate PKR both in vitro and in vivo. It is
important to note that unmodified and native yeast tRNAphe are
thought to have the same tertiary structure, [41,42,44] suggesting
that tRNA modifications may play a direct role in suppressing
PKR activation in cells, at least in this case.
Lastly, we note that eIF2a was phosphorylated to a similar level
in all four of the conditions tested: mock, dsRNA-79, tRNAphe
(Sigma), and tRNAphe (T7) (Fig. 5). Similar eIF2a behavior has
been noticed in several prior studies [27,59–61] and may reflect
the active signaling to the IFN-a/b receptor present in Huh-7
cells. Nonetheless, it is clear that only unmodified tRNAphe induces
activation of PKR, which, in turn, should lead to phosphorylation
of eIF2a.
Conclusion
PKR was originally described as the double-stranded RNA-
activated protein kinase [62]. While this moniker still holds, it has
become clear that PKR is activated by much more than dsRNA.
RNAs with complex secondary and tertiary structures activate
PKR [1,58]. Moreover, dimerization of RNA drives PKR
activation, primarily because it approximately doubles the number
of base pairs that PKR can interact with and because RNA dimers
tend to have extensive helical regions and less tertiary structure
[10,11]. In addition, most nucleoside modifications abrogate PKR
activation [30,31].
It then becomes of interest to ask not only which RNAs activate
PKR, but which RNAs do not and why? For instance, have cellular
RNAs been selected so that they do not spuriously activate PKR?
We showed in this study that unmodified or lightly modified
tRNAs, such as mt-tRNA, have an intrinsic ability to activate PKR
in vitro, but that tRNAs that are heavily modified suppress this
ability. Moreover, the dimer form of an unmodified tRNALeu
transcript can activate PKR in vitro. Dimerization of tRNA has
been long known [45–49], however functional significance of such
dimers has remained obscure. Given that nucleoside modifications
strengthen native tRNA tertiary structure [41–43], which would
resist dimerization, it is possible that RNA modifications serve, at
least in part, to help distinguish self from non-self tRNAs by
resisting RNA misfolding.
We do note that it is unclear at present whether native PKR-
activating mt-tRNAs–such as mitochondrial bovine liver total
tRNAs and mt-tRNAMet–activate PKR as dimers or monomers.
Observation that the T7 transcript of tRNALeu monomer did not
activate PKR in vitro might seem to indicate that tRNA
dimerization is critical for PKR activation; however it has been
shown elsewhere that this non-activating transcript does not fold
unless its synthetase is present [63]. Moreover, we were unable to
detect any dimers of the PKR-activating mt-tRNAMet or other mt-
tRNAs in vitro (Fig. S2 in File S1). On a related note, an
unmodified T7 human mt-tRNAMet transcript, which is very close
in sequence to the PKR-activating bovine version, adopts a
cloverleaf structure [64]. This observation strengthens the
Figure 2. Activation of PKR by tRNAs from various sources. (A) Activation assays for total tRNAs isolated from E. coli, bovine liver, yeast,
wheat, and mitochondrial bovine liver. RNA concentrations are 0.63, 1.25, 2.5, and 5 mM. (B) PKR activation for T7 transcript and natively isolated
mitochondrial tRNAs specific for methionine. RNA concentrations are 0.31, 0.63, 1.25, 2.5, and 5 mM. For each panel, a control of no RNA and a
positive control of 0.1 mM dsRNA-79 are included. Phosphorylation activities are provided below each gel lane. Phosphorylation activities were
normalized to dsRNA-79 and rounded to the nearest integer.
doi:10.1371/journal.pone.0057905.g002
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importance of having native secondary structure in monomeric
tRNA in order to activate PKR. This then suggests that RNA
modifications play dual roles in suppressing activation of PKR by
tRNA: 1.) They may help to abrogate activation when tRNA is a
monomer with native secondary structure, which is supported by
in vivo activation by natively folded yeast T7 tRNAPhe, and 2.)
They may stabilize native tertiary structure to prevent the tRNA
from dimerizing, which potentially activate PKR. Indeed, a role
for RNA modifications in suppressing PKR activation has been
reported previously for a non-dsRNA both in vitro and in vivo
[30,31].
That tRNAs capable of activating PKR exist in the human cell
but reside where PKR does not (i.e. in the mitochondria) is
consistent with the absence of selective pressure on such tRNAs to
avoid activating the innate immune system, although other
functions of the modifications such as influencing native folding
and the binding of proteins are almost certainly important. This
possibility supports the notion that modification in cellular tRNAs
function, at least in part, to suppress intrinsic activation of innate
immune responses. It will be of interest to test whether there is a
connection between tRNA from pathogens and PKR activation,
as related to the innate immune system. In addition, it will be of
interest to test whether other classes of cellular RNAs have an
intrinsic ability to activate PKR or other innate immune sensors,
and if certain cellular factors–for example, RNA modifications,
tertiary structure, or protein binding function, at least in part, to
suppress an innate immune response. The existence of the ability
to activate the innate immune system intrinsic to the sequence and
structure of a cellular RNA suggests the potential for rich
regulation of innate immunity in response to stress, disease, or
other exogenous signals that could function to unmask these
suppressed RNA signatures.
Figure 3. Analysis of hs mt-tRNALeu A14G mutant dimer formation. (A) Secondary structure of hs mt-tRNALeu in the cloverleaf representation
with the four stem-(loops) named (left-hand panel). In wild-type, the 14th position (bold font) is ‘A’, and in the pathogenic tRNA it is ‘G’. Schematic
representation of the previously reported dimeric complex formed by the pathogenic A14G hs mt-tRNALeu(UUR) mutant (right-hand panel), adopted
from ref. [49]. (B) Dimerization assay for WT and A14G pathogenic hs mt-tRNALeu. 2 mM tRNA samples in 1XTE were annealed for 5 min at the
indicated renaturation temperature, MgCl2 was added to 10 mM, and then cooled on ice. Samples were subjected to native gel electrophoresis with
running buffer 0.5X TB (45 mM Tris base and 45 mM boric acid) and stained with ethidium bromide. Positions of the previously characterized [48]
dimeric species (present only for the mutant) and the monomeric species are indicated.
doi:10.1371/journal.pone.0057905.g003
tRNA and PKR Activation
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Materials and Methods
Protein Expression and Purification
Full length PKR containing an N-terminal (His)6, which does
not interfere with binding or activation [5,57], was cloned into
pET-28a (Novagen, Inc.) and transformed into E. coli BL21 (DE3)
Rosetta cells (Novagen, Inc.) as described [5,27,57]. Briefly, cells
were sonicated and the protein was purified by a Ni2+-agarose
column (Qiagen, Inc.). PKR was dialyzed into storage buffer of
10 mM Tris-HCl (pH 7.6), 50 mM KCl, 2 mM Mg(OAc)2, 10%
Figure 4. PKR is activated by and binds tightly to A14G mt-tRNALeu dimers. (A) Activation assays for native gel purified WT monomer and
A14G dimer of mt-tRNALeu. RNA concentrations are 0.04, 0.08, 0.16, 0.32, 0.63, 1.25, 2.5, and 5 mM. A no RNA control and a positive control of 0.1 mM
dsRNA-79 are included. Phosphorylation activities are provided below each gel lane. Phosphorylation activities were normalized to dsRNA-79 and
rounded to the nearest integer. (B, C) Binding assays for dsRBD of PKR (P20) and WT and A14G mt-tRNALeu. Trace amount of 59-32P-labeled tRNA was
used in the binding experiments. Protein concentrations are 0, 0.04, 0.08, 0.16, 0.32, 0.63, 1.25, 2.5, 5, 10 and 20 mM and are present in Lanes 1 to 11,
respectively. For one set of binding experiments (B) herring sperm DNA competitor was used (0.1 mg/mL) and for the other (C) tRNA competitor was
used (0.1 mg/mL). Binding constants for A14G (#) and WT (N) in DNA competitor were 1.3 and 5.1 mM with Hill coefficients of 3.7 and 2.9
respectively, and in the presence of tRNA competitor they were 3.1 and .20 mM with Hill coefficients of 3.1 and undetermined, respectively. Higher
Hill coefficients correlate with multiple bands of lower mobility on native gels, especially in Panel C (14G); this may relate to the dimer having enough
binding registers to accommodate multiple copies of P20 at one time.
doi:10.1371/journal.pone.0057905.g004
tRNA and PKR Activation
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e57905
glycerol, and 7 mM b-mercaptoethanol (bME). Prior to PKR
activation assays, isolated protein was treated with l-protein
phosphatase (l-PPase) (NEB) as described below.
RNA Preparation and Purification
Unmodified and s2U-, m5C-, y-, m1A-, and Cm-modified
tRNAs were prepared for in vitro and in vivo experiments and
purified as reported [30]. Briefly, a T7 transcription was
conducted (Ambion) in which the corresponding modified
nucleoside triphosphate was completely substituted in the
transcription reaction. The RNAs were purified by denaturing
polyacrylamide gel electrophoresis (PAGE), identified by UV
shadowing, excised, eluted overnight, ethanol precipitated,
dissolved in TE [10 mM Tris-HCl (pH 7.5), 1 mM EDTA], and
frozen at 220uC. RNA concentrations were determined spectro-
photometrically. 29-FU-containing tRNA was prepared by an
Epicentre T7 transcription (Durascribe) kit, as previously reported
[30], and the transcript was purified as described above.
E. coli, bovine liver, yeast and wheat total and tRNAPhe-specific
tRNAs were purchased from Sigma. Total bovine liver mitochon-
drial tRNAs and methionine-specific mitochondrial tRNA (mt-
tRNAMet) were isolated as previously described using an oligonu-
cleotide with the sequence 59 TAGTACGGGAAGGATA-
TAAACCAACATTTTCGGG-biotin [65].















(Note that this transcript was prepared from a hammerhead
construct to allow efficient transcription of the gene carrying a 59A
residue, and so has a 59-OH start) [66].
T7 transcripts were labeled at their 59-ends as needed by first
treating with calf intestinal phosphatase (CIP), followed by
polynucleotide kinase (PNK) in the presence of [c-32P]ATP.
Native tRNAs from Sigma and native mt-tRNAMet were labeled at
their 39-ends using T4 RNA ligase (NEB) and [32P]-pCp.
tRNA Dimerization Assay
Native gels contained 10% of 29:1 (acrylamide: bis) crosslinking
polyacrylamide and were used to analyze the mobility differences
between monomer and dimers of tRNAs. The buffer in both the
gel and running electrophoresis was 0.56TB [50 mM Tris base,
40 mM boric acid]. Samples were fractionated between 4 and
12 h at 300 V and 16uC. Briefly, 2 mM tRNA samples in TE were
renaturated at 40, 50, 60 or 70uC for 5 min; MgCl2 was
immediately added to a final concentration of 10 mM; and
RNA was cooled on ice. Next, samples were subjected to native gel
electrophoresis with 0.56TB running buffer and stained with
ethidium bromide for visualization. (We note that employing
0.56TBE showed reduced formation of the dimer on native gels,
which may be due to sequestration of magnesium ions by EDTA
during the native gel run.).
Preparative native gel electrophoresis of tRNA dimers for PKR
activation assays followed a similar protocol. The dimer was
prepared by annealing 10 mM mt-tRNALeu (A14G) at 70uC
followed by fractionation on a 0.56TB native gel and a crush and
soak procedure similar to previously described [10].
Native Gel Mobility Shift Assay
Binding of dsRBD (P20) to tRNA monomer and dimer was
carried out by native gel mobility shift assays as described [5].
Briefly, a trace amount of 59-end labeled RNA was incubated with
various concentrations of P20 at room temperature for 10 min in
binding buffer [BB: 25 mM Hepes-KOH (pH 7.5), 10 mM NaCl,
5% glycerol, 5 mM dithiothreitol, 0.1 mM EDTA and 0.1 mg/
mL tRNAPhe (Sigma) or 0.1 mg/mL herring sperm DNA(Pro-
mega)]. Binding reactions were loaded onto a running 10% (29:1
acrylamide/bis) native gel. The gel and the running buffer
contained 0.56TB, and electrophoresis was performed at 300 V
at 16uC for 2 h. Gels were exposed to a storage screen and
analyzed on a PhosphorImager (Molecular Dynamics).
PKR Activation Assays in vitro
Modified and unmodified tRNAs, total tRNAs, and monomer
and dimers of tRNAs were tested for their ability to activate PKR
autophosphorylation. Prior to use in activation assays, T7 and
Sigma tRNAPhe were heated at 90uC for 3 min and cooled at
room temperature. All other tRNAs were used without any
renaturation prior to an activation assay, including native gel-
isolated monomer and dimer of pathogenic tRNAs, total tRNAs,
and native and T7 transcripts of mt-tRNAMet. Activation assays
were carried out largely as previously described [27,57]. Briefly,
purified PKR was dephosphorylated with l-PPase (NEB),
quenched by the addition of freshly prepared sodium orthovana-
date, and incubated with [c-32 P] ATP for 10 min at 30uC. The
time of 10 min was chosen because this is in the plateau region of
phosphorylation versus time plots [27]. Reactions were quenched
by SDS loading buffer. Samples were heated at 95uC for 5 min
and loaded onto a 10% SDS PAGE gel (Pierce). Gels were
exposed to a storage PhosphorImager screen, and bands were
quantified on a PhosphorImager (Molecular Dynamics). In all
experiments, data were normalized to the counts in a 0.1 mM of
Figure 5. Activation of PKR by yeast tRNA in vivo. Cells were
plated 8 h before transfection. Cells were transfected for 16 h with 2 mg
of either 79 bp dsRNA (lane 2), native tRNAPhe (Sigma) (lane 3), or
unmodified yeast tRNAPhe (T7) (lane 4), except in the ‘mock’ lane (lane
1) which had no RNA. The tRNA and dsRNA-79 were prepared as per
in vitro activation experiments. The ‘mock’ and ‘dsRNA-799 lanes serve
as negative and positive controls, respectively, for PKR phosphorylation.
Proteins were denatured in SDS buffer and resolved in 10% SDS-PAGE.
Phosphorylated PKR (PKR-p), phosphorylated eIF2a (eIF2a-p), and
GAPDH (loading control) were identified by Western blotting.
doi:10.1371/journal.pone.0057905.g005
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dsRNA-79 lane. Note that all activation assays in the same figure
were conducted on the same day and exposed to the same
PhosphorImager screen for the same length of time and so can be
referenced to the same dsRNA-79 reference lane.
PKR Activation Assays in vivo
Huh-7 cells were maintained as described [27]. The transfection
procedure was similar to previously described, [27] with the
following exceptions. Lysates were prepared from 16106 Huh-7
cells that were transfected for 16 h with 2 mg of the respective
RNA, prepared and renatured as described above, using DOTAP
(N-[1-(2, 3-dioleoyloxy)propyl]-N, N, N-trimethylammonium
methylsulfate) as the transfection reagent (Sigma), which has been
used recently for similar transfections [67]. The RNA was omitted
from the ‘mock’ transfection control. Cells were lysed using lysis
buffer containing 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.5%
sodium deoxycholate, 1% NP-40, 0.1% SDS and 1/100 Protease
inhibitor cocktail (Calbiochem). The lysates were further treated
with RQ1 DNase (Promega) at 37uC for 5 min and clarified by
centrifugation at 16,000 g for 10 min. A total of 25 mL of samples
were loaded for PKR-p (PKR phosphorylated at T446) and
eIF2a-p (eIF2a phosphorylated at S51) immunostaining, while
5 mL of sample was loaded for glyceraldehyde-3-phosphate
dehydrogensase (GAPDH) immunostaining. Western blotting
was performed on samples using rabbit monoclonal antibody
against PKR-pT446 (Epitomics) and eIF2a-pS51 (Epitomics) at
1:1000 dilution, and mouse monoclonal antibody GAPDH
(Fitzgerald) at 1:10,000 dilution for loading control.
Supporting Information
File S1 Supplemental material. Figure S1. Dimerization
assay of unmodified yeast tRNAPhe (T7) and native yeast tRNAPhe
(Sigma). tRNA samples (2 mM) plus trace radiolabeled tRNA in
1X TE were annealed for 3 min at 90uC, MgCl2 was added to
5 mM, and then cooled to room temperature. Samples were
subjected to native gel electrophoresis with running buffer 16
THEN100M5 (33 mM Tris (base form), 66 mM Hepes (acid form)
(pH 7.5), 0.1 mM EDTA, 100 mM NaCl, and 5 mM MgCl2).
The percent dimerization is indicated in each lane below the gel.
Very little dimer forms for either tRNA, although there is
somewhat more dimer in the T7 transcript. Figure S2.
Dimerization assay of unmodified mt-tRNAMet (T7) and native
mt-tRNAMet. Either 0.625 mM (Lanes 1, 3, 5) or 5 mM (Lanes 2, 4,
6–8) tRNA samples plus trace radiolabeled RNA in 1X TE were
renatured in lanes 1–6, as follows: samples were annealed for
5 min at 70uC, MgCl2 was added to 10 mM, and then cooled on
ice. Lanes 7 and 8 were not renatured. Samples were subjected to
native gel electrophoresis with a running buffer of 0.56 TB.
tRNAs were loaded as follows: Lanes 1, 2, and 7, native mt-
RNAMet; Lanes 3, 4, and 8, unmodified mt-tRNAMet; Lanes 5 and
6, native yeast tRNAPhe (as per Fig. S1 in File S1). No significant
dimer formed for any of these tRNAs under any of the conditions
tested. The small amount of a slower migrating band in lanes 3, 4,
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